DNA strand and cancer cell

Our March issue is live

Our March issue covers active biopharma companies and landscape feature articles covering both the fields of oncology and molecular diagnostics.

Advertisement

  • Vasomune Therapeutics has brought together decades of academic research to create a clinical-stage candidate for the treatment of diseases associated with vascular dysfunction, particularly pathogen-induced acute respiratory-distress syndrome.

    • Vasomune Therapeutics, Inc.
    Advertisement Feature
  • By coupling its expertise, scale, and technologies with those of like-minded biopharma partners GSK is striving to make a real difference for patients.

    • GSK Business Development
    Advertisement Feature
  • Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis develops predictive biomarkers to guide treatment decisions. The company’s next-generation biomarkers work for real patients by informing targeted treatment decisions for better outcomes.

    • Genialis, Inc.
    Advertisement Feature
  • MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.

    • MimiVax, Inc.
    Advertisement Feature
  • The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.

    • Brianne Sullivan
    • Andrew Davis
    • Peter Bak
    News Feature
  • Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.

    • Biopharma Dealmakers
    News Feature
  • CRISPR QC’s chip platform-enabling efficiency that aims to power the next generation of CRISPR therapies.

    • CRISPR QC
    Advertisement Feature

Advertisement

Nature Careers

Science jobs

Advertisement